BioSpace News Archive

Policy

In Latest PARP Probe, FDA Asks Clovis to Limit Rubraca’s Label

The FDA has requested that Clovis Oncology limit the indication of its PARP inhibitor Rubraca as second-line maintenance therapy in recurrent ovarian cancer.

November 17, 2022
·
2 min read
·
Tristan Manalac
Abandoned Bayer Drug Shows Preclinical Promise for Childhood Brain Tumors

New research out of McMaster University found a recently abandoned Bayer compound halted the growth of an aggressive form of pediatric medulloblastoma in mouse models.

November 17, 2022
·
4 min read
·
Kate Goodwin
Business

Immatics Falls Victim to GSK’s Receding Cell Therapy Pipeline

GSK has pulled out of its partnership focused on developing T-cell receptor therapeutics for solid tumors with Immatics, the German biotech revealed in its Q3 financial results published Thursday.

November 17, 2022
·
2 min read
·
Tristan Manalac
Business

Newly-Launched Normunity Becomes Alloy’s Latest Partner in IO Deal

Alloy Therapeutics inked an antibody discovery deal with Normunity Thursday to advance the latter’s immune normalizers, antibody therapies that boost the body’s natural immune system to fight cancer.

November 17, 2022
·
1 min read
·
Rosemary Scott
Drug Development

Astellas Scores Late-Phase Win in CLDN18.2-Positive Gastric Cancer (Updated)

Astellas’ Phase III SPOTLIGHT trial studying zolbetuximab in CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma returned positive results.

November 17, 2022
·
2 min read
·
Mark Terry
Business

Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal (Updated)

Regeneron and CytomX Therapeutics inked a deal valued at up to $2 billion to develop next-generation bispecific immunotherapies for cancer, the companies announced Thursday.

November 17, 2022
·
2 min read
·
Alex Keown
Drug Development

Editas Hits Pause on LCA10 Program in Search of Partner

Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.

November 17, 2022
·
1 min read
·
Kate Goodwin
Business

Movers & Shakers: IPI, Lucy Therapeutics, Valneva and More Add New Leaders

With the Thanksgiving season upon us, there are many reasons for biopharma and life sciences companies to say thanks, including for new leaders.

November 17, 2022
·
3 min read
·
Alex Keown
BioMidwest

Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions.

November 17, 2022
·
4 min read
Business

Valneva Appoints Dipal Patel as Chief Commercial Officer

ValnevaSE, a specialty vaccine company, announced the appointment of Dipal Patel as Chief Commercial Officer and Management Board member.

November 17, 2022
·
4 min read